In late 2013, new direct acting antivirals (DAAs) for the treatment of hepatitis C were launched worldwide. These new treatment regimens, simpler, shorter and capable of curing over 90% of people with HCV offer the perspective of making hepatitis C rare/eliminated. However, the price of those new regimens remains the main barrier to access to the 80 millions of chronically infected people worldwide.
Médecins du Monde (MdM) and Treatment Action Group (TAG) developed the project mapCrowd.org, an online crowdsourcing platform designed to help collect and share up-to-date HCV information: http://mapcrowd.org/
To mark the significance of World Hepatitis Day, Médecins du Monde (MdM) and Treatment Action Group (TAG) have produced a new report Dying at these prices: Generic HCV cure denied, based on crowdsourced hepatitis C data from over 40 countries available at mapCrowd.org.